ecancermedicalscience

Policy

Phosphoethanolamine and the danger of unproven drugs

17 Oct 2016
Noam Pondé, Evandro de Azambuja, Felipe Ades

The use of unproven forms of therapy in cancer treatment is very common. In Brazil, the distribution by researchers to patients of an investigational agent called phophoethanolamine (PHOS) has led to a widely publicized scientific scandal. PHOS is a precursor to components of the cell membrane, with some published pre-clinical studies suggesting cytotoxic activity in cancer cells. The willingness of courts and of legislators to guarantee access to PHOS in spite of the lack of any clinical data and against the recommendations of scientific and medical organisations underscores the risks that unproven agents pose to regulatory authorities, health care systems and patients, and bears resemblance to other cases such as the controversy surrounding the approval of zidovudine for AIDS treatment by the FDA.

Related Articles

Vanlaltluangi, Lalengkimi Ralte, John Zothanzama, Lalrammawia Tochhawng, Ruby Zothankimi Ralte, Harvey Vanlalpeka, Nachimuthu Senthil Kumar
Atul Budkh, Sonali Bagal, Deepak Gupta, Sharyu Mhamane, Ravikant Singh, Burhanuddin Qayyumi, Abha Rani Sinha, Sanjay Kumar Singh, Satyajit Pradhan, Pankaj Chaturvedi, Rajendra Badwe, Sudeep Gupta
Calvin R Flynn, Roselle de Guzman, Olubukola Ayodele, Joan H Schiller, Katie Lichter, E Shelley Hwang, Lisa Fox, Gustavo Gosling, Claire Hopkins, Ken Rogan, Eduardo Cazap, Seamus O’Reilly
Tenazoa -Villalobos José Richard, Yan-Quiroz Edgar Fermín, Ordoñez-Chinguel Augusto, Prado-Cucho Sofia Leonor, Villoslada-Terrones Vladimir
Camilla Engelsmann, Gitte Wooler, Vladimira Horvat, Shailesh Balasaheb Kolekar
Simran Malik, Sudipta Mukherjee, Pralay Shankar Ghosh, Santanu Bagchi, Gaurav Goel, Soumyadip Chatterji, Saugata Sen, Debashree Guha Adhya, Sangeeta Das Bhattacharya, Sanjay Bhattacharya